Approval Year
| Substance Class |
Concept
|
| Record UNII |
QU5NBP9XL3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
QU5NBP9XL3
Created by
admin on Wed Apr 02 13:39:40 GMT 2025 , Edited by admin on Wed Apr 02 13:39:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->VACCINE ANTIGEN |
On February 5, 2021 Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients with COVID-19, 83.7% effective in avoiding cases that required any medical treatment, but just 50.65% effective at preventing infection with the virus.
EFFICACY
|
